Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | CRHBP | P24387 | 4/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309629 | 0.92 | MAPT (0.62) | MAPTAKR1B10AKR1B1AKR1C4AKR1C3 | |
| SCHEMBL2130528 | 0.89 | MAPT (0.60) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16407609 | 0.87 | NPC1 (0.53) | MAPTAKR1B10AKR1B1AKR1C4AKR1C3 | |
| SCHEMBL13186987 | 0.87 | MAPT (0.61) | HTR6MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9698418 | 0.87 | HTR6 (0.58) | HTR6MAPTAKR1B10AKR1B1AKR1C4 | |
| SCHEMBL29411890 | 0.86 | AKR1B10 (0.54) | HTR6MAPTCYP1A2CYP2C9AKR1B10 | |
| SCHEMBL16407598 | 0.85 | SMN1; SMN2 (0.62) | HTR6MAPTNPSR1HTTALDH1A1 | |
| SCHEMBL7318993 | 0.83 | MAPT (0.68) | MAPTMEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL23144814 | 0.83 | MAPT (0.60) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14407558 | 0.83 | MAPT (0.58) | MAPTMEN1KMT2ACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276303-B | Ureido compounds or pharmaceutically acceptable salts thereof, and preparation method and application thereof | 河南大学 | 2023-09-22 | — | — | CN | disclosed |
| CN-114276303-A | Ureido compound or its medicinal salt and its preparing process and application | 河南大学 | 2022-04-05 | — | — | CN | disclosed |
| CN-114230529-A | Tetrahydroquinoxaline sulfonamide derivative and preparation method and application thereof | 河南大学 | 2022-03-25 | — | — | CN | disclosed |
| CN-111704579-B | Benzimidazole compound synthesis method based on iron-catalyzed redox coupling reaction | 中国农业大学 | 2021-12-14 | — | — | CN | disclosed |
| CN-111704579-A | Benzimidazole compound synthesis method based on iron-catalyzed redox coupling reaction | 中国农业大学 | 2020-09-25 | — | — | CN | disclosed |
| US-6855714-B2 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-15 | — | — | US | disclosed |
| EP-1404321-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | Schering Aktiengesellschaft (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003004023-A1 | 1-ALKYL-2-ARYL-BENZIMIDAZOLE DERIVATIVES, THEIR USE FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-16 | — | — | WO | disclosed |
| EP-0151826-B1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | ARG2, MSR1, ARG1 | HTR6 972/4885MAPT 1593/4885CYP1A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.